Gene Chip Probe Selection for Chinese Population Cancer Screening

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

There is a lack of cancer screening gene chips tailored for the Chinese population, and existing technologies for designing and optimizing gene chip probes are predominantly controlled by foreign companies, posing a challenge for developing cancer screening tools in China.

Innovation Solution

An optimal selection method for gene chip probes involves constructing a point mutation site (SNV) group, forming a candidate probe group through sequence extension and alignment, and verifying these probes to create effective gene chips for cancer screening, utilizing nucleic acid detection data and human genome big data.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If foreign companies' probe design technology is used, then cancer screening accuracy is improved, but dependence on foreign technology increases and domestic gene resource protection is compromised

Engineering Contradiction:
Improvecancer screening accuracyVSAvoidadaptability to Chinese population
Core Design Contradiction:
Measurement precisionVSAdaptability or versatility

Solution Approach 1:

The patent applies local quality by constructing a SNV group specifically from Chinese population nucleic acid detection data, and designing probes tailored to Chinese genetic characteristics. This ensures the gene chip has optimal adaptability and screening accuracy for the Chinese population while maintaining high measurement precision through population-specific probe design.

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The patent segments the probe design process into distinct stages: constructing a SNV group from Chinese cancer case data, filtering candidate probes based on specific criteria (15-25 nucleotides length, 5-10 consecutive base pairings), and validating probes against confirmed cancer cases. This systematic segmentation enables independent domestic development while achieving screening accuracy comparable to foreign technologies.

Inventive Principle:
Principle #1Segmentation

2Manufacturing precision

If a comprehensive probe selection process is implemented, then probe accuracy is improved, but development time and complexity increase

Engineering Contradiction:
Improveprobe selection accuracyVSAvoidprobe design process complexity
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent divides the complex probe design process into three manageable stages: (1) constructing a SNV group from Chinese cancer nucleic acid data, (2) selecting candidate probes with specific parameters (15-25 nt length, 5-10 consecutive base pairings, Tm value 55-65°C), and (3) validating probes against confirmed cancer cases. Each stage has clear entry and exit criteria, reducing overall process complexity while maintaining high manufacturing precision.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent establishes specific parameter ranges for candidate probes (length: 15-25 nucleotides, consecutive base pairings: 5-10, Tm value: 55-65°C) to systematically filter and select optimal probes. These quantified parameters transform the complex probe selection process into a standardized procedure that balances accuracy with manageable complexity.

Inventive Principle:
Principle #35Parameter changes

3Reliability

If population-specific gene chips are developed, then screening effectiveness for Chinese population is improved, but development challenges and technical barriers increase

Engineering Contradiction:
Improvescreening effectivenessVSAvoiddevelopment feasibility
Core Design Contradiction:
ReliabilityVSEase of manufacture

Solution Approach 1:

The patent performs preliminary actions by first constructing a comprehensive SNV group from Chinese cancer patient nucleic acid detection data and human genome big data before probe design. This preliminary data preparation and analysis create a solid foundation that simplifies subsequent probe selection and validation processes, making population-specific chip development more feasible while ensuring screening effectiveness.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent implements feedback mechanisms by validating candidate probes against confirmed cancer case data and iterating the selection process. Probe candidates are tested for their ability to correctly identify cancer cases, and selection criteria are refined based on validation results. This feedback loop ensures high screening effectiveness while providing clear guidance for probe optimization.

Inventive Principle:
Principle #23Feedback

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method enables the development of specific gene chip probes for cancer screening, allowing for early detection and intervention, reducing cancer progression and contributing to the establishment of a domestic manufacturing line for cancer screening gene chips.

Implementation Method 1

It can be used for hybridization detection of specifically labeled nucleic acids

Methodology Applied
Scientific EffectHybridization:

Implementation Method 2

The candidate probes have a length of 15-25 nucleotides and the number of base pairings is 5-10 for the longest base pairings in succession

Methodology Applied
Scientific EffectBase pairing:

Data Source

PatentUS11710537B2Optimal selection method of gene chip probes for cancer screening
Publication Date: 2023.07.25 BEIJING BIONAXIN BIOTECH CO LTD

AI summary

The invention relates to an optimal selection method of gene chip probes for cancer screening. The method is characterized in that the gene chip probes capable of being used for cancer screening are obtained through three stages of constructing a point mutation site (SNV) group, constructing a candidate probe group and verifying and confirming probes on the basis of nucleic acid data of a confirmed case of a selected cancer.